The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By

Montserrat Day Hospital Group

Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities

Nihon Nohyaku Co., Ltd.

Advised ADEKA Corporation, a global chemical manufacturer, on the acquisition of 51% stake of Nihon Nohyaku via the combination of the Tender Offer and Capital Injection

Suncorp Group Limited’s Australian Life Insurance Business

Advised TAL, Australia’s largest and leading insurance business that is 100% owned by Dai-ichi Life of Japan, on the acquisition of Suncorp Group Limited’s Australian Life Insurance business

Park Electrochemical (Electronics Business)

Advised Park Electrochemical, a leading high-performance electronics materials manufacturer, on the sale of its Electronics Business to AGC Inc.

GWA Group Limited’s Door and Access Controls Business

Advised Allegion plc, a leading global security products and solutions provider, on the acquisition of GWA Group Limited’s Door & Access Systems Business, a leading provider of door furniture and commercial locksmith services in Australia

Three Australia and New Zealand security businesses

Advised Anixter on its acquisitions of Central Security Distribution Pty Limited, Atlas Gentech (NZ) Limited and Inner Range Pty Limited

Crem International

Advised Welbilt, a leading global provider of commercial foodservice equipment on its acquisition of Crem International, a leading manufacturer of professional coffee machines

36.5% stake in DNV GL Group AS

Advised Det Norske Veritas Holding AS (“DNV”) on its acquisition of the 36.5% stake in DNV GL Group AS it did not already own from Mayfair Vermögensverwaltungs SE, whereby DNV is becoming the sole shareholder and regaining full control of DNV GL

MorphoSys AG

Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab

Godfrey Hirst

Advised Godfrey Hirst, the leading manufacturer, distributor and marketer of carpet and hard flooring in Australia and New Zealand, on its sale to Mohawk Industries, the NYSE-listed global flooring company

Jaybro

Advised Jaybro, a leading supplier of consumables to infrastructure contractors, on its sale to CHAMP Private Equity

Morris Corporation

Advised Morris Corporation, a leading independent player in Australia’s remote facilities management sector, on its sale to Sodexo SA, a France-based leading global facilities services company

Programmed Maintenance Services Limited

Advised PERSOL HOLDINGS, one of Japan’s largest HR service companies, on its acquisition of ASX-listed Programmed Maintenance Services, a leading Australian and New Zealand based provider of staffing and maintenance services

Inenco Group Pty Ltd

Advised Inenco Group Pty Ltd, one of Australasia’s leading industrial distributors, on the partial sale to Genuine Parts Company, a global distributor of automotive and industrial products

The Franklin Printing Group Pty Ltd (“Franklin Web”) and Taverners No.13 Pty Ltd (“AIW Printing”)

Advised ASX-listed IVE Group, a leading marketing and print communications provider in Australia, on the simultaneous acquisitions of Franklin Web and AIW Printing, specialist catalogue producers, and its equity capital raising via a placement and a rights issue

Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)

Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).

Bionomics Limited

Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.

US rights to 37 approved and 5 pipeline generic products

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products

US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila

US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.

Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories

Brasil/CT

Advised Brasil/CT on a capital injection made by Invest Tech in the Company. Brasil/CT specializes in the e-commerce market and is a leader in B2C and B2B full-commerce and loyalty operations in Brazil. Invest Tech is an investment manager focused on venture capital and private equity in the technology and telecom sectors

Divestment assets of Ball and Rexam

Advised Ball Corporation on the acquisition of Rexam plc and provided a fairness opinion to the Board of Directors of Ball Corporation on the sale of select metal beverage can assets in Europe, Brazil and the United States to satisfy certain regulatory requirements in connection with its proposed acquisition of Rexam

Sewells Group

Advised WorldMark on the sale of Sewells Group to MSX International, a global provider of outsourced business solutions. Sewells, headquartered in Shanghai, is a leading provider of automotive dealership development services across Asia Pacific, Africa and the Middle East

COOEC Fluor Heavy Industries Co., Ltd.

Advised Fluor Corporation on its $489 million investment for a 49% interest in a joint venture with Offshore Oil Engineering Co., Ltd. (COOEC) to own, operate and manage the Zhuhai Fabrication Yard in China’s Guangdong province